Fulminant liver failure due to severe veno-occlusive disease after haematopoietic cell transplantation: A depressing experience

QJM: An International Journal of Medicine

Volumn 97, Issue 9, 2004, Pages 581-589

  MacQuillan, G C ^a   Mutimer, David ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTIBIOTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEFIBROTIDE; DOXORUBICIN; ETOPOSIDE; HEPARIN; MELPHALAN; METHIONINE; RETINOIC ACID; TISSUE PLASMINOGEN ACTIVATOR; URSODEOXYCHOLIC ACID;

ADULT; AUTOPSY; BLEEDING; BRAIN DISEASE; CARDIOMYOPATHY; CHEMOTHERAPY; CLINICAL ARTICLE; DEATH; DISEASE COURSE; DISEASE SEVERITY; DRUG MEGADOSE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTENSIVE CARE; LIVER BIOPSY; LIVER FAILURE; LIVER TRANSPLANTATION; LIVER VEIN OBSTRUCTION; MALE; MULTIPLE ORGAN FAILURE; PATIENT REFERRAL; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; REVIEW;

EID: 4544275118     PISSN: 14602725     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/hch095     Document Type: Review

References (52)

1. Willmot F, Robertson G. Senecio disease, or cirrhosis of the liver due to senecio poisoning. Lancet 1920; 2:848-9.
2. Selzer G, Parker R. Senecio poisoning exhibiting as Chiari's syndrome: a report on twelve cases. Am J Pathol 1950; 27:885-7.
3. Bras G, Jeliffe D, Stuart K. Veno-occlusive disease of the liver with non-portal type of cirrhosis ocurring in Jamica. Arch Pathol 1954; 57:285-300.
4. Berk PD, Popper H, Krueger GR, Decter J, Herzig G, Graw RG Jr. Veno-occlusive disease of the liver after allogenic bone marrow transplantation. Ann Intern Med 1979; 90:158-64.
5. King PD, Perry MC. Hepatotoxicity of chemotherapy. Oncologist 2001; 6:162-76.
6. McDonald GB, Slattery JT, Bouvier ME, Ren S, Batchelder AL, Kalhorn TF, Schoch HG, Anasetti C, Gooley T. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003; 101:2043-8.
7. Katzka DA, Saul SH, Jorkasky D, Sigal H, Reynolds JC, Soloway RD. Azathioprine and hepatic venocclusive disease in renal transplant patients. Gastroenterology 1986; 90:446-54.
8. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 2002; 22:27-42.
9. Shulman HM, Fisher LB, Schoch HG, Henne KW, McDonald GB. Veno-occlusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms. Hepatology 1994; 19:1171-81.
10. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, Hardin BJ, Shulman HM, Clift RA. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118:255-67.
11. Rollins BJ. Hepatic veno-occlusive disease. Am J Med 1986; 81:297-306.
12. Remberger M, Ringden O. Cytokines in veno-occlusive disease of the liver after bone marrow transplantation. Transplant Proc 1995; 27:3533-4.
13. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97:3390-400.
14. Strasser SI, Myerson D, Spurgeon CL, Sullivan KM, Storer B, Schoch HG, Kim S, Flowers ME, McDonald GB. Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up. Hepatology 1999; 29:1893-9.
15. Baglin TP. Veno-occlusive disease of the liver complicating bone marrow transplantation. Bone Marrow Transplant 1994; 13:1-4.
16. Essell JH, Schroeder MT, Harman GS, Halvorson R, Lew V, Callander N, Snyder M, Lewis SK, Allerton JP, Thompson JM. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128:975-81.
17. Ruutu T, Eriksson B, Remes K, Juvonen E, Volin L, Remberger M, et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002; 100:1977-83.
18. Bearman SI, Anderson GL, Mori M, Hinds MS, Shulman HM, McDonald GB. Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 1993; 11:1729-36.
19. Carreras E, Bertz H, Arcese W, et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 1998; 92:3599-604.
20. Rubenfeld GD, Crawford SW. Withdrawing life support from mechanically ventilated recipients of bone marrow transplants: a case for evidence-based guidelines. Ann Intern Med 1996; 125:625-33.
21. Blostein MD, Paltiel OB, Thibault A, Rybka WB. A comparison of clinical criteria for the diagnosis of veno-occlusive disease of the liver after bone marrow transplantation. Bone Marrow Transplant 1992; 10:439-43.
22. Carreras E, Granena A, Navasa M, Bruguera M, Marco V, Sierra J, Tassies MD, Garcia-Pagan JC, Marti JM, Bosch J, Rodes J, Rozman C. On the reliability of clinical criteria for the diagnosis of hepatic veno-occlusive disease. Ann Hematol 1993; 66:77-80.
23. Carreras E, Granena A, Navasa M, Bruguera M, Marco V, Sierra J, Tassies MD, Garcia-Pagan JC, Marti JM, Bosch J, Rodes J, Rozman C. Transjugular liver biopsy in BMT. Bone Marrow Transplant 1993; 11:21-6.
24. Shulman HM, Gooley T, Dudley MD, Kofler T, Feldman R, Dwyer D, McDonald GB. Utility of transvenous liver biopsies and wedged hepatic venous pressure measurements in sixty marrow transplant recipients. Transplantation 1995; 59:1015-22.
25. Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE, York RC, Lin LS, Devine SM, Geller RB, Heffner LT, Hillyer CD, Holland HK, Winton EF, Saral R. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996; 17:225-30.
26. Toh HC, McAfee SL, Sackstein R, Cox BF, Colby C, Spitzer TR. Late onset veno-occlusive disease following high-dose chemotherapy and stem cell transplantation. Bone Marrow Transplant 1999; 24:891-5.
27. Shimoni A, Bielorai B, Toren A, Hardan I, Avigdor A, Yeshurun M, Ben-Bassat I, Nagler A. Intravenous busulfan-based conditioning prior to allogeneic hematopoietic stem cell transplantation: myeloablation with reduced toxicity. Exp Hematol 2003; 31:428-34.
28. Marsa-Vila L, Gorin NC, Laporte JP, Labopin M, Dupuy-Montbrun MC, Fouillard L, Isnard F, Najman A. Prophylactic heparin does not prevent liver veno-occlusive disease following autologous bone marrow transplantation. Eur J Haematol 1991; 47:346-54.
29. Or R, Nagler A, Shpilberg O, Elad S, Naparstek E, Kapelushnik J, Cass Y, Gillis S, Chetrit A, Slavin S, Eldor A. Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients. Transplantation 1996; 61:1067-71.
30. Forrest DL, Thompson K, Dorcas VG, Couban SH, Pierce R. Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: a prospective phase II study. Bone Marrow Transplant 2003; 31:1143-9.
31. Ohashi K, Tanabe J, Watanabe R, Tanaka T, Sakamaki H, Maruta A, Okamoto S, Aotsuka N, Saito K, Nishimura M, Oh H, Matsuzaki M, Takahashi S, Yonekura S. The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation. Am J Hematol 2000; 64:32-8.
32. Hong RW, Rounds JD, Helton WS, Robinson MK, Wilmore DW. Glutamine preserves liver glutathione after lethal hepatic injury. Ann Surg 1992; 215:114-19.
33. Brown SA, Goringe A, Fegan C, Davies SV, Giddings J, Whittaker JA, Burnett AK, Poynton CH. Parenteral glutamine protects hepatic function during bone marrow transplantation. Bone Marrow Transplant 1998; 22:281-4.
34. DeLeve LD, Wang X, Kuhlenkamp JF, Kaplowitz N. Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: the role of glutathione and relevance to hepatic venoocclusive disease. Hepatology 1996; 23:589-99.
35. DeLeve LD. Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation. Hepatology 1996; 24:830-7.
36. Ringden O, Remberger M, Lehmann S, Hentschke P, Mattsson J, Klaesson S, Aschan J. N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation. Bone Marrow Transplant 2000; 25:993-6.
37. Bearman SI, Lee JL, Baron AE, McDonald GB. Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood 1997; 89:1501-6.
38. Hagglund H, Ringden O, Ericzon BG, Duraj F, Ljungman P, Lonnqvist B, Winiarski J, Tyden G. Treatment of hepatic venoocclusive disease with recombinant human tissue plasminogen activator or orthotopic liver transplantation after allogeneic bone marrow transplantation. Transplantation 1996; 62:1076-80.
39. Palmer KJ, Goa KL. Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders.2 Drugs 1993; 45:259-94.
40. Falanga A, Vignoli A, Marchetti M, Barbui T. Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells. Leukemia 2003; 17:1636-42.
41. Richardson PG, Elias AD, Krishnan A, Wheeler C, Nath R, Hoppensteadt D, Kinchla NM, Neuberg D, Waller EK, Antin JH, Soiffer R, Vredenburgh J, Lill M, Woolfrey AE, Bearman SI, Iacobelli M, Fareed J, Guinan EC. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood 1998; 92:737-44.
42. Richardson PG, Murakami C, Jin Z, Warren DL, Momtaz P, Hoppensteadt D, Elias AD, Antin JH, Soiffer RJ, Spitzer TR, Avigan D, Bearman SI, Martin PL, Kurtzberg J, Vredenburgh J, Chen AR, Arai S, Vogelsang G, McDonald GB, Guinan EC. Multi-institutional use of defibrotide in 88 patients post stem cell transplant with severe veno-occlusive disease and multi-system organ failure; response without significant toxicity in a high risk population and factors predictive of outcome. Blood 2002; 100:4337-43.
43. Mor E, Pappo O, Bar-Nathan N, Shaharabani E, Shapira Z, Tur-Kaspa R, Ben-Ari Z. Defibrotide for the treatment of veno-occlusive disease after liver transplantation. Transplantation 2001; 72:1237-40.
44. Azoulay D, Castaing D, Lemoine A, Hargreaves GM, Bismuth H. Transjugular intrahepatic portosystemic shunt (TIPS) for severe veno-occlusive disease of the liver following bone marrow transplantation. Bone Marrow Transplant 2000; 25:987-92.
45. Fried MW, Connaghan DG, Sharma S, Martin LG, Devine S, Holland K, Zuckerman A, Kaufman S, Wingard J, Boyer TD. Transjugular intrahepatic portosystemic shunt for the management of severe venoocclusive disease following bone marrow transplantation. Hepatology 1996; 24:588-91.
46. Bunin N, Leahey A, Dunn S. Related donor liver transplant for veno-occlusive disease following T-depleted unrelated donor bone marrow transplantation. Transplantation 1996; 61:664-6.
47. Dowlati A, Honore P, Damas P, Deprez M, Delwaide J, Fillet G, Beguin Y. Hepatic rejection after orthotopic liver transplantation for hepatic veno-occlusive disease or graft-versus-host disease following bone marrow transplantation. Transplantation 1995; 60:106-9.
48. Nimer SD, Milewicz AL, Champlin RE, Busuttil RW. Successful treatment of hepatic venoocclusive disease in a bone marrow transplant patient with orthotopic liver transplantation. Transplantation 1990; 49:819-21.
49. Rapoport AP, Doyle HR, Starzl T, Rowe JM, Doeblin T, DiPersio JF. Orthotopic liver transplantation for life-threatening veno-occlusive disease of the liver after allogeneic bone marrow transplant. Bone Marrow Transplant 1991; 8:421-4.
50. Rosen HR, Martin P, Schiller GJ, Territo M, Lewin DN, Shackleton CR, Busuttil RW. Orthotopic liver transplantation for bone-marrow transplant-associated veno-occlusive disease and graft-versus-host disease of the liver. Liver Transpl Surg 1996; 2:225-32.
51. Salat C, Holler E, Wolf C, Kolb HJ, Reinhardt B, Pihusch R, Kramling HJ, Heinemann V, Haller M, Hiller E. Laboratory markers of veno-occlusive disease in the course of bone marrow and subsequent liver transplantation. Bone Marrow Transplant 1997; 19:487-90.
52. Schlitt HJ, Tischler HJ, Ringe B, Raddatz G, Maschek H, Dietrich H, Kuse E, Pichlmayr R, Link H. Allogeneic liver transplantation for hepatic veno-occlusive disease after bone marrow transplantation-clinical and immunological considerations. Bone Marrow Transplant 1995; 16:473-8.